Gilead Sciences

American biopharmaceutical company

GILD Nasdaq ISIN US3755581036 SEC CIK 882095 LEI 549300WTZWR07K8MNV44
Follow Gilead Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $8.3B +6.8% vs same quarter last year
Net income $2.4B −20.4% vs same quarter last year
EPS, diluted $1.94 −20.2% vs same quarter last year
Operating cash flow $5B +22.6% vs same quarter last year
Revenue by quarter
$7.6B
$6.7B
$7.1B
$7.8B
$7.9B
$7B
$7.8B
$8.3B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
$0$10B$20B$30B$40BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$29.4B$8.5B
FY24$28.8B$480M
FY23$27.1B$5.7B
FY22$27.3B$4.6B
FY21$27.3B$6.2B
FY20$24.7B$123M
FY19$22.4B$5.4B
FY18$22.1B$5.5B
FY17$26.1B$4.6B
FY16$30.4B$13.5B
FY15$32.6B$18.1B
FY14$24.9B$12.1B
FY13$11.2B$3.1B
FY12$9.7B$2.6B
FY11$8.4B$2.8B
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
0%25%50%75%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2578.8%34%28.9%
FY2478.3%5.8%1.7%
FY2376%28%20.9%
FY2279.3%26.9%16.8%
FY2175.8%36.3%22.8%
FY2081.5%16.5%0.5%
FY1979.2%19.1%24%
FY1878.1%37.1%24.7%
FY1783.3%54.1%17.7%
FY1686%58%44.4%
FY1587.7%68%55.5%
FY1484.8%61.3%48.6%
FY1374.5%40.4%27.5%
FY1274.5%41.3%26.7%
FY1174.7%45.2%33.4%
Free cash flowOperating cash flow minus capital expenditure
$0$10B$20B$30BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$9.5B
FY24$10.3B
FY23$7.4B
FY22$8.3B
FY21$10.8B
FY20$7.5B
FY19$8.3B
FY18$7.5B
FY17$11.3B
FY16$16.3B
FY15$20.5B
FY14$12.3B
FY13$3B
FY12$2.8B
FY11$3.5B
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$5B$10B$15BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearDividendsBuybacks
FY25$4B$1.9B
FY24$3.9B$1.2B
FY23$3.8B$1B
FY22$3.7B$1.4B
FY21$3.6B$546M
FY20$3.4B$1.6B
FY19$3.2B$1.7B
FY18$3B$2.9B
FY17$2.7B$954M
FY16$2.5B$11B
FY15$1.9B$10B
FY14$0$5.3B
FY13$0$582M
FY12-$667M
FY11-$2.4B
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Gilead Sciences
  • Healthcare median
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGilead SciencesHealthcare median
FY2528.9%−30.6%
FY241.7%−47%
FY2320.9%−58%
FY2216.8%−80.4%
FY2122.8%−71.9%
FY200.5%−62.2%
FY1924%−46.3%
FY1824.7%−49.6%
FY1717.7%−45.9%
FY1644.4%−36%
FY1555.5%−38.4%
FY1448.6%−35.5%
FY1327.5%−37.1%
FY1226.7%−29.1%
FY1133.4%−27.9%